Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine.
AIDS has remained a significant and worsening medical problem since its first description as a new clinical entity in 1981. In the past 6 years, substantial progress has been made in the chemotherapy for this disease; such progress is likely to exert a major effect on the epidemic of human immunodeficiency virus infection in the coming decade. In this article, we overview the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine (didanosine; ddI), which has recently been shown in early phase I studies to have activity against human immunodeficiency virus in patients with AIDS or AIDS-related complex. Although we will not know the full clinical potential of ddI until we have the results of ongoing controlled clinical trials, this drug appears to possess desirable features for clinical use.
McGowan
J J
JJ
AIDS Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Tomaszewski
J E
JE
Cradock
J
J
Hoth
D
D
Grieshaber
C K
CK
Broder
S
S
Mitsuya
H
H
D000818:Animals; D016049:Didanosine / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D016048:Dideoxyadenosine / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D006678:HIV / Q000187:drug effects*; D006801:Humans
D016048:Dideoxyadenosine; D016049:Didanosine